Studies risankizumab treatment in adults with moderate to severe ulcerative colitis
Observes how risankizumab works in adults with ulcerative colitis during routine care.
Plain-language title generated from the registry record
Registry title: Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Key facts
- Where
- Ahaus, Altenburg, Altenholz, Andernach, Berlin, Bochum, Buedelsdorf, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Geesthacht, Halle, Hamburg, Hanover, Heide, Heidelberg, Herne, Jena, Jerichow, Karlsruhe, Kiel, Koblenz, Leipzig, Leverkusen, Lübeck, Ludwigshafen am Rhein, Magdeburg, Minden, Münster, Neumünster, Nordhausen, Pirmasens, Potsdam, Schwerin, Solingen, Teuchern, Tostedt, Wesseling, Witten, Wriezen, and Würselen, GermanySee the 57 sites
Where in Germany
- Medizinisches Versorgungszentrum Ahaus /ID# 280966Ahaus, GermanyTaking people
- Klinikum Altenburger Land /ID# 283912Altenburg, GermanyTaking people
- Gemeinschaftspraxis im Medicum /ID# 275933Altenholz, GermanyTaking people
- Praxis Heil & Mueller /ID# 275927Andernach, GermanyTaking people
- Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 275884Berlin, GermanyTaking people
- Dres. Schick/Wesenberg /ID# 275878Berlin, GermanyTaking people
- Drk Kliniken Berlin - Kopenick /ID# 276277Berlin, GermanyTaking people
- Facharztpraxis fur Gastroenterologie Karlshorst /ID# 277966Berlin, GermanyTaking people
- Gastro Studien GbR /ID# 275920Berlin, GermanyTaking people
- Gastroenterologie im Muhlenbergviertel /ID# 275883Berlin, GermanyTaking people
- Krankenhaus Waldfriede /ID# 275913Berlin, GermanyTaking people
- Praxis Dr. Soellenboehmer /ID# 276183Berlin, GermanyTaking people
- Praxis Dr. Spitz /ID# 275912Berlin, GermanyTaking people
- Private Practice - Dr. Jeannette Schwenzer & Dr. Sven Gruengreiff /ID# 276089Berlin, GermanyTaking people
- Private Practice- Dr. Andreas Horn /ID# 281448Berlin, GermanyTaking people
- Gastropraxis Bochum /ID# 281375Bochum, GermanyTaking people
- Katholisches Klinikum Bochum gGmbH /ID# 279486Bochum, GermanyTaking people
- Praxis S. Tetzlaff /ID# 275882Buedelsdorf, GermanyTaking people
- Evangelisches Krankenhaus Kalk /ID# 276414Cologne, GermanyTaking people
- Private Practice - Dr. Johannes Janschek /ID# 275877Dresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf /ID# 280409Düsseldorf, GermanyTaking people
- Dres. Bauer/Doerflinger /ID# 276093Freiburg im Breisgau, GermanyTaking people
- Praxis Dr. Guenther-Tritsch /ID# 275886Geesthacht, GermanyTaking people
- Private Practice - Dr. Thomas Zeisler /ID# 277933Halle, GermanyTaking people
- Studiengesellschaft Mitteldeutschland /ID# 275905Halle, GermanyTaking people
- Gastroenterologie Rahlstedt /ID# 276408Hamburg, GermanyTaking people
- Private Practice - Dr. Matthias Eichler /ID# 275875Hamburg, GermanyTaking people
- Gastroenterologische Schwerpunktpraxis - Hannover /ID# 276701Hanover, GermanyTaking people
- Diabetologie Dithmarschen /ID# 281104Heide, GermanyTaking people
- Universitaetsklinikum Heidelberg /ID# 275906Heidelberg, GermanyTaking people
- GSGH Gastroenterologische Studiengesellschaft Herne GbR /ID# 275874Herne, GermanyTaking people
- Dr. Jack Peter-Stein /ID# 276815Jena, GermanyTaking people
- Praxisgemeinschaft Jerichow Schulze /ID# 275911Jerichow, GermanyTaking people
- Gastroenterologe am Ettlinger Tor /ID# 279854Karlsruhe, GermanyTaking people
- Private Practice - Dr. Thormann & Dr. Bethge /ID# 275931Kiel, GermanyTaking people
- Gastroenterologische Gemeinschaftspraxis Im Loehr-Center Koblenz /ID# 275943Koblenz, GermanyTaking people
- Dres. Breitschwerdt/Glas/Gurtler /ID# 276057Leipzig, GermanyTaking people
- Gesellschaft für klinische Studien /ID# 275867Leipzig, GermanyTaking people
- Universitaetsklinikum Leipzig /ID# 276779Leipzig, GermanyTaking people
- MVZ Gastroenterologie Leverkusen /ID# 275901Leverkusen, GermanyTaking people
- Praxis fuer Gastroenterologie - Lubeck /ID# 275903Lübeck, GermanyTaking people
- Gastroenterologische Schwerpunkt Praxis /ID# 279856Ludwigshafen am Rhein, GermanyTaking people
- Gastropraxis Magdeburg /ID# 275885Magdeburg, GermanyTaking people
- Dres. Kamp & Partner /ID# 275904Minden, GermanyTaking people
- Bettenworth & Partner /ID# 275900Münster, GermanyTaking people
- Fek - Friedrich-Ebert-Krankenhaus Neumunster /ID# 276105Neumünster, GermanyTaking people
- Tumorzentrum Nordthuringen Medizinisches Versorgungszentrum /ID# 280072Nordhausen, GermanyTaking people
- Pc Docs /Id# 275876Pirmasens, GermanyTaking people
- Klinikum Ernst Von Bergmann /ID# 278268Potsdam, GermanyTaking people
- Praxis fuer Gastroenterologie - Schwerin /ID# 275946Schwerin, GermanyTaking people
- Dres. Rehbehn/Skusa /ID# 276090Solingen, GermanyTaking people
- Private Practice - Dr. Jaqueline Schumann /ID# 276126Teuchern, GermanyTaking people
- Private Practice - Dr. Kempelmann /ID# 275726Tostedt, GermanyTaking people
- Private Practice - Dr. Markus Braunfels /ID# 277129Wesseling, GermanyTaking people
- Gemeinschaftspraxis Innere Medizin /ID# 280068Witten, GermanyTaking people
- Private Practice Dr. Katharina Pfeifer /ID# 286373Wriezen, GermanyTaking people
- Dr. Schirin-Sokhan /ID# 276982Würselen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06764706
- Record updated
- 22 October 2026
- Original description
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice.Read full original descriptionShow less
A Prospective, Real-World Study EvalUating the EffectiveNess and Safety of RISankizumab in PatiEnts With Ulcerative Colitis (SUNRISE-UC)
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice.
Risankizumab is an approved drug for treating participants with ulcerative colitis. Approximately 200 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately multiple sites across Germany and Austria.
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 52 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis; Participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label.
Exclusion: Participants previously exposed risankizumab; Participants who are currently participating in interventional research (not including noninterventional studies, post-marketing observational study (PMOS), or registry participation).